amlodipine has been researched along with Albuminuria in 82 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to assess the effects of irbesartan alone and combined with amlodipine, efonidipine, or trichlormethiazide on blood pressure (BP) and urinary albumin (UA) excretion in hypertensive patients with microalbuminuria (30≤UA/creatinine (Cr) ratio [UACR] <300 mg/g Cr) and upper-normal microalbuminuria (10≤UACR<30 mg/g Cr)." | 9.27 | Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients. ( Asayama, K; Hanazawa, T; Hosaka, M; Imai, Y; Inoue, R; Obara, T; Ohkubo, T; Satoh, M; Watabe, D, 2018) |
| "To examine the antihypertensive efficacy and safety of indapamide sustained-release (SR)/amlodipine compared with enalapril/amlodipine in patients 65 years and older with uncontrolled blood pressure (BP) on monotherapy, a post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria) was conducted." | 9.24 | Blood pressure-lowering efficacy of indapamide SR/amlodipine combination in older patients with hypertension: A post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria). ( Boully, C; Caillard, L; Chaussade, E; Hanon, O; Hernandorena, I, 2017) |
| "Hypertensive diabetic patients with microalbuminuria were included in this retrospective, post-hoc analysis of the Natrilix SR Versus Enalapril Study in Hypertensive Type 2 Diabetics With MicrOalbuminuRia (NESTOR) trial if they were uncontrolled on monotherapy (indapamide slow release (SR) 1." | 9.20 | Treatment of Hypertensive Patients With Diabetes and Microalbuminuria With Combination Indapamide SR/Amlodipine: Retrospective Analysis of NESTOR. ( Boully, C; Caillard, L; Chaussade, E; Cochiello, S; Hanon, O; Labourée, F, 2015) |
| "The present study failed to demonstrate the non-inferiority of the antialbuminuric effect of benidipine relative to that of hydrochlorothiazide in RAS inhibitor-treated hypertensive patients with macroalbuminuria." | 9.19 | Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr ( Ando, K; Fujita, T; Isshiki, M; Kashihara, N; Nakanishi, T; Nangaku, M; Nishizawa, Y; Nitta, K; Rakugi, H; Shimosawa, T; Takahashi, K; Tomita, K; Yokoyama, H, 2014) |
| " We conducted an open-label, randomized trial to compare the effects of cilnidipine against those of amlodipine on blood pressure (BP), albuminuria, and plasma aldosterone concentration in hypertensive patients with mild- to moderate-stage chronic kidney disease." | 9.17 | L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. ( Abe, M; Inoshita, A; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Yoshida, Y, 2013) |
| "In accordance with experimental data after antihypertensive treatment of 4 weeks, intraglomerular pressure was significantly lower with the CCB manidipine than with amlodipine, resulting and explaining their disparate effects on albuminuria." | 9.17 | Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. ( Alberici, M; Ott, C; Raff, U; Ritt, M; Schmieder, RE; Schneider, MP; Striepe, K, 2013) |
| "We examined blood pressure reduction and metabolic alterations after amlodipine/benazepril and valsartan/hydrochlorothiazide treatment in patients with type 2 diabetes mellitus and hypertension and microalbuminuria." | 9.16 | Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012) |
| " Hypertensive patients with type 2 diabetes mellitus and albuminuria (≥30 mg g(-1) creatinine) were enroled in the study, and were either started on or switched to candesartan (8 mg per day) monotherapy." | 9.16 | Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria. ( Dohi, Y; Ichikawa, T; Ito, M; Kato, T; Kimura, G; Kojima, M; Komada, T; Machida, H; Miyazaki, T; Nakatani, K; Ninomiya, T; Okura, T; Sugiyama, M; Watanabe, Y, 2012) |
| " In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD)." | 9.15 | Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. ( Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M, 2011) |
| " Albuminuria was significantly reduced by manidipine (-37." | 9.14 | Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study. ( Martínez Martín, FJ, 2009) |
| "The aim of this study was to compare the efficacy and safety of adding manidipine 20 mg versus amlodipine 10 mg to the treatment of diabetic patients with uncontrolled hypertension and microalbuminuria despite full-dose treatment with a renin-angiotensin system blocker for at least 6 months." | 9.13 | Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. ( Martinez-Martin, FJ; Saiz-Satjes, M, 2008) |
| "These results suggest that cilnidipine is more effective than amlodipine at improving renal function and arterial stiffness in patients with essential hypertension." | 9.12 | Renal and vascular protective effects of cilnidipine in patients with essential hypertension. ( Iwasaka, T; Maki, K; Morimoto, S; Yano, Y, 2007) |
| "Aim of this study was to evaluate the effect of the telmisartan-amlodipine combination at different doses on urinary albumin excretion rate (UAER) in hypertensive diabetic patients with microalbuminuria." | 9.12 | Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. ( Derosa, G; Destro, M; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "We selected 453 hypertensive patients with type 2 diabetes and microalbuminuria and randomized them to amlodipine (5 to 15 mg/day), fosinopril (10 to 30 mg/day), or amlodipine plus fosinopril (5/10 to 15/30 mg/day) for a 3-month titration period." | 9.10 | Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Marasi, G; Mugellini, A; Pasotti, C; Poletti, L; Preti, P; Rinaldi, A; Voglini, C; Zoppi, A, 2002) |
| "Three hundred thirty-two patients with type 2 diabetes and microalbuminuria, with or without hypertension, were randomly assigned to 80 mg/d valsartan or 5 mg/d amlodipine for 24 weeks." | 9.10 | Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. ( Viberti, G; Wheeldon, NM, 2002) |
| "Eplerenone is a highly selective aldosterone blocker, which is under development for the treatment of hypertension and heart failure." | 9.10 | Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. ( Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB, 2003) |
| "The objectives of this study were to evaluate the effects of an ACE inhibitor (fosinopril) and a calcium antagonist (amlodipine) on the urinary albumin and transferrin excretion and their relationship to the blood pressure in essential hypertension." | 9.08 | Albuminuria and transferrinuria in essential hypertension. Effects of antihypertensive therapy. ( Agrati, AM; Alli, C; Cassani, M; Granata, S; Lombardo, M; Zanni, D, 1996) |
| " The metabolic and renal effects of long-term (8 months) therapy with amlodipine, 5 to 10 mg daily, were studied in 15 hypertensive patients with uncomplicated diabetes mellitus as compared with 15 patients with essential hypertension." | 9.07 | Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. ( Beretta-Piccoli, C; Heinen, G; Pingitore, R; Riesen, W; Zanetti-Elshater, F, 1994) |
| "We hypothesized that compared with hydrochlorothiazide (HCTZ), the renin inhibitor aliskiren (ALISK) or amlodipine (AMLO) and their combination reduce albuminuria via reduction in renal inflammation, independent of blood pressure (BP) changes." | 7.78 | Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats. ( Huang, J; Matavelli, LC; Siragy, HM, 2012) |
| "These results demonstrate that benidipine favourably affects renal function in patients with essential hypertension compared with amlodipine, suggesting that the clinical benefits of benidipine as an antihypertensive drug include a renoprotective effect." | 7.75 | Effects of benidipine, a long-acting T-type calcium channel blocker, on home blood pressure and renal function in patients with essential hypertension: a retrospective, 'real-world' comparison with amlodipine. ( Hoshino, C; Kikuchi, A; Kuriyama, C; Ohta, M; Sato, N; Sugawara, S, 2009) |
| " Combination therapy of valsartan with either amlodipine or verapamil was equally effective in reducing blood pressure to valsartan monotherapy (valsartan + amlodipine 129 +/- 4 valsartan + verapamil 133 +/- 6 mmHg;) but was not as effective at reducing albuminuria." | 7.72 | Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. ( Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003) |
| "Amlodipine had an antihypertensive effect in cats with coexistent systemic hypertension and renal insufficiency." | 7.71 | Effects of the calcium channel antagonist amlodipine in cats with surgically induced hypertensive renal insufficiency. ( Brown, CA; Brown, SA; Cartier, LM; Elliot, J; Mathur, S; Moore, PA; Munday, JS; Newell, MA; Sheldon, SE; Syme, H, 2002) |
| " The present study was designed to investigate whether calcium channel blockers (CCBs) in combination with an ARB differentially affect kidney function." | 6.75 | Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine. ( Dohi, Y; Kimura, G; Miyagawa, K; Nakazawa, A; Sato, K; Sugiura, T; Yamashita, S, 2010) |
| "The aim of this study was to assess the effects of irbesartan alone and combined with amlodipine, efonidipine, or trichlormethiazide on blood pressure (BP) and urinary albumin (UA) excretion in hypertensive patients with microalbuminuria (30≤UA/creatinine (Cr) ratio [UACR] <300 mg/g Cr) and upper-normal microalbuminuria (10≤UACR<30 mg/g Cr)." | 5.27 | Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients. ( Asayama, K; Hanazawa, T; Hosaka, M; Imai, Y; Inoue, R; Obara, T; Ohkubo, T; Satoh, M; Watabe, D, 2018) |
| "Cilnidipine did not show any additional anti-albuminuric effect compared with amlodipine in patients with T2D and microalbuminuria treated with an RAS blocker." | 5.24 | Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial. ( Cha, BS; Chung, CH; Hwang, YC; Jang, HC; Lee, KW; Lee, MK; Min, KW; Yoon, KH, 2017) |
| "In AMANDHA trial, the addition of manidipine, but not amlodipine, in diabetic patients with uncontrolled hypertension, microalbuminuria and preserved renal function resulted in a large decrease of urinary albumin excretion (UAE) despite similar blood pressure (BP) reductions." | 5.24 | Factors associated with the reduction of albumin excretion in diabetic hypertensive patients: differential effect of manidipine versus amlodipine. ( Martinez-Martin, FJ; Roca-Cusachs, A; Saiz-Satjes, M, 2017) |
| "To examine the antihypertensive efficacy and safety of indapamide sustained-release (SR)/amlodipine compared with enalapril/amlodipine in patients 65 years and older with uncontrolled blood pressure (BP) on monotherapy, a post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria) was conducted." | 5.24 | Blood pressure-lowering efficacy of indapamide SR/amlodipine combination in older patients with hypertension: A post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria). ( Boully, C; Caillard, L; Chaussade, E; Hanon, O; Hernandorena, I, 2017) |
| "Albuminuria was significantly reduced, compared with baseline values, with the lercanidipine + enalapril combination over the entire study period; at month 3, month 6 and month 12, changes from baseline were: -162." | 5.22 | Lercanidipine valuable effect on urine protein losses: the RED LEVEL study. ( Calvo, C; Espinel, E; Esteban, R; Macias, JF; Mateos, L; Robles, NR; Sobrino, J, 2016) |
| "Hypertensive diabetic patients with microalbuminuria were included in this retrospective, post-hoc analysis of the Natrilix SR Versus Enalapril Study in Hypertensive Type 2 Diabetics With MicrOalbuminuRia (NESTOR) trial if they were uncontrolled on monotherapy (indapamide slow release (SR) 1." | 5.20 | Treatment of Hypertensive Patients With Diabetes and Microalbuminuria With Combination Indapamide SR/Amlodipine: Retrospective Analysis of NESTOR. ( Boully, C; Caillard, L; Chaussade, E; Cochiello, S; Hanon, O; Labourée, F, 2015) |
| "The aim of this study was to compare the effects of a dihidropiridin calcium channel blocker amlodipin and a non-dihidropiridin calcium channel blocker verapamil on nephropathy and serum pigment epithelium-derived factor (PEDF) levels of type 2 diabetic patients with hypertension." | 5.20 | The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus. ( Çelik, H; Korkmaz, H; Oğuz, E; Sabuncu, T; Tabur, S, 2015) |
| "The present study failed to demonstrate the non-inferiority of the antialbuminuric effect of benidipine relative to that of hydrochlorothiazide in RAS inhibitor-treated hypertensive patients with macroalbuminuria." | 5.19 | Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr ( Ando, K; Fujita, T; Isshiki, M; Kashihara, N; Nakanishi, T; Nangaku, M; Nishizawa, Y; Nitta, K; Rakugi, H; Shimosawa, T; Takahashi, K; Tomita, K; Yokoyama, H, 2014) |
| "In this prospective, multicenter, open-labeled, randomized trial, the antialbuminuric effects of cilnidipine and amlodipine were examined in renin-angiotensin system (RAS) inhibitor-treated patients with hypertension (blood pressure [BP]: 130-180/80-110 mmHg), type 2 diabetes, and microalbuminuria (urinary albumin to creatinine [Cr] ratio [UACR]: 30-300 mg/g)." | 5.17 | Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial. ( Ando, K; Fujita, T; Kosugi, S; Matsuoka, H; Nakao, K; Sato, T; Tanaka, S; Ueshima, K, 2013) |
| "We conducted a quasi-experimental, validation study in which patients with primary, uncomplicated hypertension received open-label, fixed combination therapy with amlodipine/losartan 5/50 mg or 5/100 mg according to their baseline blood pressure (BP)." | 5.17 | Echocardiographic changes and treatment goal rates after a 6-month combined treatment with amlodipine and losartan: a validation study in Andean countries (METAL study). ( Pérez Carreño, JG; Romero, JD; Villar Centeno, JC, 2013) |
| "Hypertensive patients with type 2 diabetes mellitus and microalbuminuria under treatment with a combination of a standard dose of telmisartan (40 mg/day) and trichlormethiazide (1 mg/day) were randomly assigned to receive either an increased dose of telmisartan (80 mg/day) combined with trichlormethiazide [increased dose angiotensin receptor blocker (ARB) group, n = 20] or a combination consisting of telmisartan (40 mg/day), trichlormethiazide, and amlodipine (5 mg/day) (triple combination group, n = 20) for 6 months." | 5.17 | Titration of telmisartan, but not addition of amlodipine, reduces urine albumin in diabetic patients treated with telmisartan-diuretic. ( Dohi, Y; Kimura, G; Kojima, M; Ohashi, M, 2013) |
| " We conducted an open-label, randomized trial to compare the effects of cilnidipine against those of amlodipine on blood pressure (BP), albuminuria, and plasma aldosterone concentration in hypertensive patients with mild- to moderate-stage chronic kidney disease." | 5.17 | L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. ( Abe, M; Inoshita, A; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Yoshida, Y, 2013) |
| "In accordance with experimental data after antihypertensive treatment of 4 weeks, intraglomerular pressure was significantly lower with the CCB manidipine than with amlodipine, resulting and explaining their disparate effects on albuminuria." | 5.17 | Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. ( Alberici, M; Ott, C; Raff, U; Ritt, M; Schmieder, RE; Schneider, MP; Striepe, K, 2013) |
| "We examined blood pressure reduction and metabolic alterations after amlodipine/benazepril and valsartan/hydrochlorothiazide treatment in patients with type 2 diabetes mellitus and hypertension and microalbuminuria." | 5.16 | Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012) |
| " Hypertensive patients with type 2 diabetes mellitus and albuminuria (≥30 mg g(-1) creatinine) were enroled in the study, and were either started on or switched to candesartan (8 mg per day) monotherapy." | 5.16 | Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria. ( Dohi, Y; Ichikawa, T; Ito, M; Kato, T; Kimura, G; Kojima, M; Komada, T; Machida, H; Miyazaki, T; Nakatani, K; Ninomiya, T; Okura, T; Sugiyama, M; Watanabe, Y, 2012) |
| " In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD)." | 5.15 | Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. ( Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M, 2011) |
| "5-5 mg/day) in olmesartan-treated hypertensive (blood pressure 130-180/80-110 mmHg) patients with type 2 diabetes (fasting blood sugar ≥126 mg/dL or treatment with antidiabetic agents) and albuminuria (urinary albumin/creatinine ratio ≥30 mg/g)." | 5.15 | Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action ( Ando, K; Fujita, T; Haneda, M; Ito, S; Kashihara, N; Kishimoto, J; Nangaku, M; Node, K; Shimosawa, T, 2011) |
| " To elucidate our hypothesis, we designed a multi-center, open-labeled, randomized trial to compare the antialbuminuric effect between cilnidipine and amlodipine in RAS inhibitor-treated hypertensive (blood pressure [BP]: 130-180/80-110 mmHg) patients with type 2 diabetes and microalbuminuria (urinary albumin/creatinine [Cr] ratio: 30-300 mg/g)." | 5.15 | Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial. ( Ando, K; Babazono, T; Fujita, T; Kario, K; Matsuoka, H; Nakao, K; Tanaka, S; Ueshima, K, 2011) |
| " 11 506 patients with hypertension who were at high risk for cardiovascular events were randomly assigned via a central, telephone-based interactive voice response system in a 1:1 ratio to receive benazepril (20 mg) plus amlodipine (5 mg; n=5744) or benazepril (20 mg) plus hydrochlorothiazide (12." | 5.14 | Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. ( Bakris, GL; Chiang, YT; Dahlöf, B; Jamerson, K; Kelly, RY; Pitt, B; Sarafidis, PA; Shi, V; Staikos-Byrne, L; Velazquez, EJ; Weber, MA; Weir, MR, 2010) |
| " Albuminuria was significantly reduced by manidipine (-37." | 5.14 | Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study. ( Martínez Martín, FJ, 2009) |
| " We hypothesized that a trandolapril/verapamil SR (T/V) fixed-dose combination (FDC) was superior to a benazepril/amlodipine (B/A) FDC for reducing albuminuria in 304 hypertensive diabetic nephropathy patients when treated for 36 weeks." | 5.13 | Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. ( Bacher, P; Champion, A; Fakouhi, K; Tian, M; Toto, RD, 2008) |
| "The aim of this study was to compare the efficacy and safety of adding manidipine 20 mg versus amlodipine 10 mg to the treatment of diabetic patients with uncontrolled hypertension and microalbuminuria despite full-dose treatment with a renin-angiotensin system blocker for at least 6 months." | 5.13 | Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. ( Martinez-Martin, FJ; Saiz-Satjes, M, 2008) |
| " In this study, we administered amlodipine 5 mg or 10 mg to patients with hypertension in order to compare the efficacy and tolerability of low and high doses, and measured two surrogate markers of hypertensive target organ damage, i." | 5.13 | Effects of strict blood pressure control by a long-acting calcium channel blocker on brain natriuretic peptide and urinary albumin excretion rate in Japanese hypertensive patients. ( Hoshide, S; Ishikawa, J; Ishikawa, S; Kabutoya, T; Kario, K; Shimada, K; Uno, H, 2008) |
| "Aim of this study was to evaluate the effect of the telmisartan-amlodipine combination at different doses on urinary albumin excretion rate (UAER) in hypertensive diabetic patients with microalbuminuria." | 5.12 | Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. ( Derosa, G; Destro, M; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "These results suggest that cilnidipine is more effective than amlodipine at improving renal function and arterial stiffness in patients with essential hypertension." | 5.12 | Renal and vascular protective effects of cilnidipine in patients with essential hypertension. ( Iwasaka, T; Maki, K; Morimoto, S; Yano, Y, 2007) |
| "The renoprotective effect of candesartan is considered more favorable than amlodipine in the treatment of ADPKD." | 5.11 | Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. ( Higaki, Y; Higashihara, E; Horie, S; Hosoya, T; Kamura, K; Mochizuki, T; Nakayama, T; Nutahara, K; Shimizu, T; Tsuchiya, K; Yamamoto, N, 2005) |
| "These results suggest that in type 2 diabetes with overt nephropathy, 24-h blood pressure regulation alone is inadequate to reduce macroalbuminuria and additional effects of losartan are crucial for antiproteinuric action." | 5.11 | Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. ( Ando, D; Hirawa, N; Tochikubo, O; Umemura, S; Yasuda, G, 2005) |
| " A new clinical trial, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension), is designed to compare the change in urinary albumin to creatinine ratio after 1 year of initial treatment with either amlodipine besylate/benazepril HCl or benazepril HCl/hydrochlorothiazide." | 5.11 | Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. ( Bakris, GL; McCullough, PA; Toto, RD, 2005) |
| "Three hundred thirty-two patients with type 2 diabetes and microalbuminuria, with or without hypertension, were randomly assigned to 80 mg/d valsartan or 5 mg/d amlodipine for 24 weeks." | 5.10 | Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. ( Viberti, G; Wheeldon, NM, 2002) |
| "We selected 453 hypertensive patients with type 2 diabetes and microalbuminuria and randomized them to amlodipine (5 to 15 mg/day), fosinopril (10 to 30 mg/day), or amlodipine plus fosinopril (5/10 to 15/30 mg/day) for a 3-month titration period." | 5.10 | Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Marasi, G; Mugellini, A; Pasotti, C; Poletti, L; Preti, P; Rinaldi, A; Voglini, C; Zoppi, A, 2002) |
| "Eplerenone is a highly selective aldosterone blocker, which is under development for the treatment of hypertension and heart failure." | 5.10 | Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. ( Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB, 2003) |
| "The objectives of this study were to evaluate the effects of an ACE inhibitor (fosinopril) and a calcium antagonist (amlodipine) on the urinary albumin and transferrin excretion and their relationship to the blood pressure in essential hypertension." | 5.08 | Albuminuria and transferrinuria in essential hypertension. Effects of antihypertensive therapy. ( Agrati, AM; Alli, C; Cassani, M; Granata, S; Lombardo, M; Zanni, D, 1996) |
| "Effects of losartan and amlodipine on blood pressure and albuminuria were compared in a randomized, double-blind, parallel trial involving 48 patients with essential hypertension (sitting diastolic blood pressure between 95 to 115 mm Hg) and impaired renal function (creatinine clearance of 30 to 60 ml/min/1." | 5.08 | Comparison of losartan and amlodipine in renally impaired hypertensive patients. ( Aranda, P; Casado, S; Fernández-Andrade, C; Guerra, L; Iversen, B; Russo, D; Zucchelli, P, 1998) |
| "The objective of this study was to examine the effects of angiotensin II receptor blocker losartan versus the calcium channel blocker amlodipine on proteinuria, renal haemodynamics, glomerular sieving and tubular function in hypertensive patients with non-diabetic nephropathy." | 5.08 | Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. ( Berg, KJ; Fauchald, P; Hartmann, A; Holdaas, H; Lund, K, 1998) |
| " The metabolic and renal effects of long-term (8 months) therapy with amlodipine, 5 to 10 mg daily, were studied in 15 hypertensive patients with uncomplicated diabetes mellitus as compared with 15 patients with essential hypertension." | 5.07 | Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. ( Beretta-Piccoli, C; Heinen, G; Pingitore, R; Riesen, W; Zanetti-Elshater, F, 1994) |
| " The Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA-2) study, the Reduction of End Points in Non-Insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study, and the Irbesartan Type 2 Diabetic Nephropathy Trial (IDNT) indicate that AIIAs postpone the progression of type 2 diabetic renal disease at all stages, ranging from microproteinuria to overt nephropathy and ESRD, RENAAL showed that losartan improves renal outcomes in patients with type 2 DM and nephropathy over and above that attributable to BP control alone." | 4.82 | Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. ( Ruilope, LM; Segura, J, 2003) |
| "We hypothesized that compared with hydrochlorothiazide (HCTZ), the renin inhibitor aliskiren (ALISK) or amlodipine (AMLO) and their combination reduce albuminuria via reduction in renal inflammation, independent of blood pressure (BP) changes." | 3.78 | Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats. ( Huang, J; Matavelli, LC; Siragy, HM, 2012) |
| "These results demonstrate that benidipine favourably affects renal function in patients with essential hypertension compared with amlodipine, suggesting that the clinical benefits of benidipine as an antihypertensive drug include a renoprotective effect." | 3.75 | Effects of benidipine, a long-acting T-type calcium channel blocker, on home blood pressure and renal function in patients with essential hypertension: a retrospective, 'real-world' comparison with amlodipine. ( Hoshino, C; Kikuchi, A; Kuriyama, C; Ohta, M; Sato, N; Sugawara, S, 2009) |
| " Combination therapy of valsartan with either amlodipine or verapamil was equally effective in reducing blood pressure to valsartan monotherapy (valsartan + amlodipine 129 +/- 4 valsartan + verapamil 133 +/- 6 mmHg;) but was not as effective at reducing albuminuria." | 3.72 | Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. ( Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003) |
| "Amlodipine had an antihypertensive effect in cats with coexistent systemic hypertension and renal insufficiency." | 3.71 | Effects of the calcium channel antagonist amlodipine in cats with surgically induced hypertensive renal insufficiency. ( Brown, CA; Brown, SA; Cartier, LM; Elliot, J; Mathur, S; Moore, PA; Munday, JS; Newell, MA; Sheldon, SE; Syme, H, 2002) |
| "Seventy-six patients with type 2 diabetes and DKD (all with albuminuria and serum creatinine <1." | 2.78 | Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria. ( Gnudi, L; Hill, B; Karalliedde, J; Maltese, G; Viberti, G, 2013) |
| " The present study was designed to investigate whether calcium channel blockers (CCBs) in combination with an ARB differentially affect kidney function." | 2.75 | Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine. ( Dohi, Y; Kimura, G; Miyagawa, K; Nakazawa, A; Sato, K; Sugiura, T; Yamashita, S, 2010) |
| "Hypertensive patients with type 2 diabetes and microalbuminuria were randomly assigned to valsartan or amlodipine treatment groups for 24 weeks." | 2.73 | Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART). ( Kashiwagi, A; Maegawa, H; Sawaguchi, M; Uzu, T, 2008) |
| " The dosage was doubled if necessary." | 2.71 | Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. ( Bianchetti, MG; Edefonti, A; Fossali, E; Gartenmann, AC; Schmidtko, J; Simonetti, GD; von Vigier, RO, 2003) |
| "Twenty-eight patients who had type 1 diabetes and known diabetic renal disease and had a persistently elevated albumin creatinine ratio (ACR) > 10 mg/mmol despite office BP recordings < or = 140/80 mmHg on maximal recommended dose of the ACEI lisinopril were studied." | 2.71 | Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease. ( Bilous, R; Karalliedde, J; Krimholtz, MJ; Thomas, S; Viberti, G, 2005) |
| "Although proteinuria has been considered a surrogate of renal disease progression, further studies will be necessary to confirm this hypothesis in ADPKD, because after 5 years, no differences in renal function were observed between the enalapril and amlodipine groups." | 2.69 | Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. ( Brosnahan, GM; Chapman, AB; Ecder, T; Edelstein, CL; Johnson, AM; Schrier, RW, 2000) |
| "Amlodipine is a classical drug with varied properties extending from control of blood pressure to as an antianginal and anti atherosclerotic agent." | 2.58 | Amlodipine in the Era of New Generation Calcium Channel Blockers. ( Kashyap, R; Langote, A; Tiwaskar, M; Toppo, A, 2018) |
| "Diabetic nephropathy is associated with increased albuminuria and accumulation of extracellular matrix proteins within the kidney." | 1.32 | Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes. ( Allen, TJ; Cao, Z; Cooper, ME; Ma, G, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (8.54) | 18.2507 |
| 2000's | 36 (43.90) | 29.6817 |
| 2010's | 39 (47.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanon, O | 2 |
| Caillard, L | 2 |
| Chaussade, E | 2 |
| Hernandorena, I | 1 |
| Boully, C | 2 |
| Hwang, YC | 1 |
| Yoon, KH | 1 |
| Cha, BS | 1 |
| Lee, KW | 1 |
| Jang, HC | 1 |
| Min, KW | 1 |
| Chung, CH | 1 |
| Lee, MK | 1 |
| Hosaka, M | 1 |
| Inoue, R | 1 |
| Satoh, M | 1 |
| Watabe, D | 1 |
| Hanazawa, T | 1 |
| Ohkubo, T | 1 |
| Asayama, K | 1 |
| Obara, T | 1 |
| Imai, Y | 1 |
| Tiwaskar, M | 1 |
| Langote, A | 1 |
| Kashyap, R | 1 |
| Toppo, A | 1 |
| Karalliedde, J | 3 |
| Maltese, G | 1 |
| Hill, B | 1 |
| Viberti, G | 4 |
| Gnudi, L | 1 |
| Ando, K | 4 |
| Ueshima, K | 2 |
| Tanaka, S | 2 |
| Kosugi, S | 1 |
| Sato, T | 1 |
| Matsuoka, H | 3 |
| Nakao, K | 2 |
| Fujita, T | 5 |
| Pérez Carreño, JG | 1 |
| Romero, JD | 1 |
| Villar Centeno, JC | 1 |
| Fogari, R | 3 |
| Derosa, G | 3 |
| Zoppi, A | 3 |
| Lazzari, P | 3 |
| D'Angelo, A | 1 |
| Mugellini, A | 3 |
| Sweiss, N | 1 |
| Sharma, K | 1 |
| Nitta, K | 2 |
| Rakugi, H | 1 |
| Nishizawa, Y | 1 |
| Yokoyama, H | 1 |
| Nakanishi, T | 1 |
| Kashihara, N | 2 |
| Tomita, K | 1 |
| Nangaku, M | 2 |
| Takahashi, K | 1 |
| Isshiki, M | 1 |
| Shimosawa, T | 2 |
| Tabur, S | 1 |
| Oğuz, E | 1 |
| Sabuncu, T | 1 |
| Korkmaz, H | 1 |
| Çelik, H | 1 |
| Uchida, S | 1 |
| Takahashi, M | 2 |
| Sugawara, M | 1 |
| Saito, T | 1 |
| Nakai, K | 1 |
| Fujita, M | 1 |
| Mochizuki, K | 1 |
| Shin, I | 1 |
| Morita, T | 1 |
| Hikita, T | 1 |
| Itakura, H | 1 |
| Takahashi, Y | 1 |
| Mizuno, S | 1 |
| Ohno, Y | 1 |
| Ito, K | 1 |
| Ito, T | 1 |
| Soma, M | 4 |
| Labourée, F | 1 |
| Cochiello, S | 1 |
| Robles, NR | 1 |
| Calvo, C | 1 |
| Sobrino, J | 1 |
| Espinel, E | 1 |
| Esteban, R | 1 |
| Mateos, L | 1 |
| Macias, JF | 1 |
| Saiz-Satjes, M | 2 |
| Martinez-Martin, FJ | 2 |
| Roca-Cusachs, A | 1 |
| Uno, H | 1 |
| Ishikawa, J | 1 |
| Hoshide, S | 1 |
| Kabutoya, T | 1 |
| Ishikawa, S | 1 |
| Shimada, K | 1 |
| Kario, K | 2 |
| Uzu, T | 2 |
| Sawaguchi, M | 2 |
| Maegawa, H | 2 |
| Kashiwagi, A | 2 |
| Toto, RD | 3 |
| Tian, M | 1 |
| Fakouhi, K | 1 |
| Champion, A | 1 |
| Bacher, P | 1 |
| Kaneshiro, Y | 2 |
| Ichihara, A | 2 |
| Sakoda, M | 2 |
| Kurauchi-Mito, A | 1 |
| Kinouchi, K | 1 |
| Itoh, H | 2 |
| Martínez Martín, FJ | 1 |
| Ohta, M | 1 |
| Sugawara, S | 1 |
| Sato, N | 1 |
| Kuriyama, C | 1 |
| Hoshino, C | 1 |
| Kikuchi, A | 1 |
| Miyagawa, K | 1 |
| Dohi, Y | 3 |
| Nakazawa, A | 1 |
| Sugiura, T | 1 |
| Yamashita, S | 1 |
| Sato, K | 1 |
| Kimura, G | 3 |
| Bakris, GL | 5 |
| Sarafidis, PA | 1 |
| Weir, MR | 1 |
| Dahlöf, B | 1 |
| Pitt, B | 1 |
| Jamerson, K | 1 |
| Velazquez, EJ | 1 |
| Staikos-Byrne, L | 1 |
| Kelly, RY | 1 |
| Shi, V | 1 |
| Chiang, YT | 1 |
| Weber, MA | 2 |
| Konoshita, T | 1 |
| Makino, Y | 1 |
| Kimura, T | 1 |
| Fujii, M | 1 |
| Wakahara, S | 1 |
| Arakawa, K | 1 |
| Inoki, I | 1 |
| Nakamura, H | 1 |
| Miyamori, I | 1 |
| Liang, W | 1 |
| Chen, C | 1 |
| Shi, J | 1 |
| Ren, Z | 1 |
| Hu, F | 1 |
| van Goor, H | 1 |
| Singhal, PC | 1 |
| Ding, G | 1 |
| Aritomi, S | 1 |
| Koganei, H | 1 |
| Wagatsuma, H | 1 |
| Mitsui, A | 1 |
| Ogawa, T | 1 |
| Konda, T | 1 |
| Abe, M | 3 |
| Okada, K | 3 |
| Maruyama, N | 3 |
| Matsumoto, S | 1 |
| Maruyama, T | 1 |
| Matsumoto, K | 1 |
| Okura, T | 1 |
| Kojima, M | 2 |
| Machida, H | 1 |
| Sugiyama, M | 1 |
| Kato, T | 1 |
| Komada, T | 1 |
| Miyazaki, T | 1 |
| Ninomiya, T | 1 |
| Ichikawa, T | 1 |
| Nakatani, K | 1 |
| Watanabe, Y | 1 |
| Ito, M | 2 |
| Holtkamp, FA | 1 |
| de Zeeuw, D | 1 |
| de Graeff, PA | 1 |
| Laverman, GD | 1 |
| Berl, T | 1 |
| Remuzzi, G | 1 |
| Packham, D | 1 |
| Lewis, JB | 1 |
| Parving, HH | 1 |
| Lambers Heerspink, HJ | 1 |
| Haneda, M | 1 |
| Ito, S | 1 |
| Node, K | 1 |
| Kishimoto, J | 1 |
| Babazono, T | 1 |
| Hiroo, K | 1 |
| Oda, T | 1 |
| Kushiyama, T | 1 |
| Higashi, K | 1 |
| Yamamoto, K | 1 |
| Rodríguez-Pérez, JC | 1 |
| García-Bello, MA | 1 |
| Anabitarte-Prieto, A | 1 |
| Companioni, O | 1 |
| Nóvoa-Mogollón, FJ | 1 |
| Suárez-Ortega, S | 1 |
| Plaza-Toledano, C | 1 |
| Rodríguez-Esparragón, F | 1 |
| Takano, H | 1 |
| Hasegawa, H | 1 |
| Narumi, H | 1 |
| Shindo, S | 1 |
| Mizuma, H | 1 |
| Kuwabara, Y | 1 |
| Kobayashi, Y | 1 |
| Komuro, I | 1 |
| Matavelli, LC | 1 |
| Huang, J | 1 |
| Siragy, HM | 1 |
| Maeda, A | 1 |
| Tamura, K | 1 |
| Kanaoka, T | 1 |
| Ohsawa, M | 1 |
| Haku, S | 1 |
| Azushima, K | 1 |
| Dejima, T | 1 |
| Wakui, H | 1 |
| Yanagi, M | 1 |
| Okano, Y | 1 |
| Fujikawa, T | 1 |
| Toya, Y | 1 |
| Mizushima, S | 1 |
| Tochikubo, O | 2 |
| Umemura, S | 2 |
| Suzuki, H | 2 |
| Fujii, Y | 1 |
| Yoshida, Y | 2 |
| Daikuhara, H | 1 |
| Kikuchi, F | 1 |
| Ishida, T | 1 |
| Soeki, T | 1 |
| Kitani, M | 1 |
| Kusunose, K | 1 |
| Yagi, S | 1 |
| Taketani, Y | 1 |
| Koshiba, K | 1 |
| Wakatsuki, T | 1 |
| Orino, S | 1 |
| Kawano, K | 1 |
| Sata, M | 1 |
| Lee, IT | 1 |
| Hung, YJ | 1 |
| Chen, JF | 1 |
| Wang, CY | 1 |
| Lee, WJ | 1 |
| Sheu, WH | 1 |
| Inoshita, A | 1 |
| Ohashi, M | 1 |
| Chatzikyrkou, C | 1 |
| Menne, J | 1 |
| Ott, C | 1 |
| Schneider, MP | 1 |
| Raff, U | 1 |
| Ritt, M | 1 |
| Striepe, K | 1 |
| Alberici, M | 1 |
| Schmieder, RE | 1 |
| Ay, SA | 1 |
| Cakar, M | 1 |
| Karaman, M | 1 |
| Balta, S | 1 |
| Demirkol, S | 1 |
| Unlu, M | 1 |
| Kurt, O | 1 |
| Altun, B | 1 |
| Akhan, M | 1 |
| Arslan, E | 1 |
| Koc, B | 1 |
| Bulucu, F | 1 |
| Wheeldon, NM | 1 |
| Preti, P | 2 |
| Rinaldi, A | 2 |
| Corradi, L | 1 |
| Pasotti, C | 1 |
| Poletti, L | 1 |
| Marasi, G | 1 |
| Voglini, C | 1 |
| Davis, BJ | 1 |
| Cao, Z | 2 |
| de Gasparo, M | 1 |
| Kawachi, H | 1 |
| Cooper, ME | 2 |
| Allen, TJ | 2 |
| White, WB | 1 |
| Duprez, D | 1 |
| St Hillaire, R | 1 |
| Krause, S | 1 |
| Roniker, B | 1 |
| Kuse-Hamilton, J | 1 |
| Gartenmann, AC | 1 |
| Fossali, E | 1 |
| von Vigier, RO | 1 |
| Simonetti, GD | 1 |
| Schmidtko, J | 1 |
| Edefonti, A | 1 |
| Bianchetti, MG | 1 |
| Ruilope, LM | 1 |
| Segura, J | 1 |
| Lehfeld, LS | 1 |
| Silveira, LA | 1 |
| Ghini, B | 1 |
| Lopes de Faria, JB | 1 |
| Ma, G | 1 |
| McCullough, PA | 2 |
| Nutahara, K | 1 |
| Higashihara, E | 1 |
| Horie, S | 1 |
| Kamura, K | 1 |
| Tsuchiya, K | 1 |
| Mochizuki, T | 1 |
| Hosoya, T | 1 |
| Nakayama, T | 1 |
| Yamamoto, N | 1 |
| Higaki, Y | 1 |
| Shimizu, T | 1 |
| Winer, N | 1 |
| Folker, A | 1 |
| Murphy, JA | 1 |
| Hung, E | 2 |
| Bard, M | 1 |
| Perkelvald, A | 1 |
| Sowers, JR | 1 |
| Krimholtz, MJ | 1 |
| Thomas, S | 1 |
| Bilous, R | 1 |
| Wei, L | 1 |
| Tan, J | 1 |
| Yasuda, G | 1 |
| Ando, D | 1 |
| Hirawa, N | 1 |
| Ishimitsu, T | 1 |
| Kobayashi, T | 1 |
| Honda, T | 1 |
| Minami, J | 1 |
| Ohta, S | 1 |
| Inada, H | 1 |
| Yoshii, M | 1 |
| Ono, H | 1 |
| Destro, M | 1 |
| Fogari, E | 1 |
| Takemitsu, T | 1 |
| Morimoto, S | 1 |
| Yano, Y | 1 |
| Maki, K | 1 |
| Iwasaka, T | 1 |
| Rocha, R | 1 |
| Purkayastha, D | 1 |
| Davis, P | 1 |
| Smith, A | 1 |
| DeAngelis, L | 1 |
| Mirenda, V | 1 |
| Kandra, A | 1 |
| Botha, J | 1 |
| Ferber, P | 1 |
| Ranieri, G | 1 |
| Andriani, A | 1 |
| Lamontanara, G | 1 |
| De Cesaris, R | 1 |
| Zanetti-Elshater, F | 1 |
| Pingitore, R | 1 |
| Beretta-Piccoli, C | 1 |
| Riesen, W | 1 |
| Heinen, G | 1 |
| Letizia, C | 1 |
| De Ciocchis, A | 1 |
| Cerci, S | 1 |
| Coassin, S | 1 |
| Fisher, H | 1 |
| Tarsitani, P | 1 |
| Scavo, D | 1 |
| Alli, C | 1 |
| Lombardo, M | 1 |
| Zanni, D | 1 |
| Agrati, AM | 1 |
| Cassani, M | 1 |
| Granata, S | 1 |
| Waeber, B | 1 |
| Weidmann, P | 1 |
| Wohler, D | 1 |
| Le Bloch, Y | 1 |
| Fernández-Andrade, C | 1 |
| Russo, D | 1 |
| Iversen, B | 1 |
| Zucchelli, P | 1 |
| Aranda, P | 1 |
| Guerra, L | 1 |
| Casado, S | 1 |
| Holdaas, H | 1 |
| Hartmann, A | 1 |
| Berg, KJ | 1 |
| Lund, K | 1 |
| Fauchald, P | 1 |
| Ecder, T | 1 |
| Chapman, AB | 1 |
| Brosnahan, GM | 1 |
| Edelstein, CL | 1 |
| Johnson, AM | 1 |
| Schrier, RW | 1 |
| Shigihara, T | 1 |
| Sato, A | 1 |
| Hayashi, K | 1 |
| Saruta, T | 1 |
| Lamarre-Cliche, M | 1 |
| Lambert, R | 1 |
| Van Nguyen, P | 1 |
| Cusson, J | 1 |
| Wistaff, R | 1 |
| Larochelle, P | 1 |
| Smith, AC | 1 |
| Richardson, DJ | 1 |
| Preston, R | 1 |
| Goldberg, R | 1 |
| Epstein, M | 1 |
| Studney, D | 1 |
| Mathur, S | 1 |
| Syme, H | 1 |
| Brown, CA | 1 |
| Elliot, J | 1 |
| Moore, PA | 1 |
| Newell, MA | 1 |
| Munday, JS | 1 |
| Cartier, LM | 1 |
| Sheldon, SE | 1 |
| Brown, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| A 24-week Study to Evaluate the Effectiveness of Valsartan in Combination With Hydrochlorothiazide Versus Amlodipine on Arterial Compliance in Patients With Hypertension, Type 2 Diabetes and Albuminuria[NCT00171561] | Phase 4 | 144 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Evaluation of Hematologic Patients - Training Protocol[NCT00001715] | 898 participants (Actual) | Observational | 1998-04-21 | Completed | |||
| The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART)[NCT00202618] | Phase 4 | 160 participants | Interventional | 2003-12-31 | Recruiting | ||
| A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension[NCT00170950] | Phase 3 | 11,506 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.) | ||
| Efficacy and Safety of Two Fixed-combination Antihypertensive Regimens, Amtrel® and Co-Diovan® in Type 2 Diabetes Hypertension Patients With Microalbuminuria[NCT01375322] | Phase 4 | 226 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy[NCT00295555] | Phase 4 | 98 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 5.0 |
| Benazepril/Hydrochlorothiazide | 6.3 |
Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 8.6 |
| Benazepril/Hydrochlorothiazide | 10.3 |
CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an event (Number) |
|---|---|
| Benazepril/Amlodipine | 9.6 |
| Benazepril/Hydrochlorothiazide | 11.8 |
5 reviews available for amlodipine and Albuminuria
| Article | Year |
|---|---|
Amlodipine in the Era of New Generation Calcium Channel Blockers.
Topics: Albuminuria; Amlodipine; Atherosclerosis; Calcium Channel Blockers; Diabetes Complications; Diabetic | 2018 |
Adiponectin effects on the kidney.
Topics: Adiponectin; Albuminuria; Amlodipine; AMP-Activated Protein Kinases; Animals; Benzimidazoles; Benzoa | 2014 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trial | 2003 |
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
65 trials available for amlodipine and Albuminuria
| Article | Year |
|---|---|
Blood pressure-lowering efficacy of indapamide SR/amlodipine combination in older patients with hypertension: A post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria).
Topics: Aged; Aged, 80 and over; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes | 2017 |
Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial.
Topics: Adult; Aged; Albuminuria; Amlodipine; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropy | 2017 |
Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients.
Topics: Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pr | 2018 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
Topics: Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Ca | 2013 |
Echocardiographic changes and treatment goal rates after a 6-month combined treatment with amlodipine and losartan: a validation study in Andean countries (METAL study).
Topics: Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, | 2013 |
Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria.
Topics: Adult; Aged; Albuminuria; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agent | 2014 |
Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr
Topics: Adult; Aged; Albuminuria; Amlodipine; Blood Pressure; Dihydropyridines; Female; Glomerular Filtratio | 2014 |
The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Amlodipine; Blood Pressure; Calcium Channel Blockers; Creatinine; Diabetes Mellit | 2015 |
Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study).
Topics: Aged; Aged, 80 and over; Albuminuria; Amlodipine; Blood Pressure; Calcium Channel Blockers; Creatini | 2014 |
Treatment of Hypertensive Patients With Diabetes and Microalbuminuria With Combination Indapamide SR/Amlodipine: Retrospective Analysis of NESTOR.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Ca | 2015 |
Lercanidipine valuable effect on urine protein losses: the RED LEVEL study.
Topics: Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Double-Bli | 2016 |
Factors associated with the reduction of albumin excretion in diabetic hypertensive patients: differential effect of manidipine versus amlodipine.
Topics: Adult; Aged; Albumins; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Me | 2017 |
Effects of strict blood pressure control by a long-acting calcium channel blocker on brain natriuretic peptide and urinary albumin excretion rate in Japanese hypertensive patients.
Topics: Albuminuria; Amlodipine; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C-Reacti | 2008 |
Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART).
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2008 |
Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convertin | 2008 |
Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Be | 2008 |
Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan.
Topics: Adult; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, | 2009 |
Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Antihypertensive Agents; Blood | 2009 |
Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.
Topics: Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyper | 2010 |
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Be | 2010 |
A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker.
Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin I; Angiotensin II; Blood Pressure; Calcium C | 2010 |
Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria.
Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calciu | 2011 |
Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidaz | 2012 |
Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action
Topics: Adult; Aged; Albuminuria; Amlodipine; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetic N | 2011 |
Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
Topics: Aged; Albuminuria; Amlodipine; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, | 2011 |
[The Shiga Microalbuminuria Reduction Trial].
Topics: Albuminuria; Amlodipine; Animals; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephr | 2010 |
Anti-albuminuric effects of the angiotensin AT1 receptor blocker telmisartan in hypertensive patients.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; An | 2011 |
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressur | 2012 |
Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ben | 2012 |
Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Albuminuria; Aldosterone; Amides; Amlodipine; Angiotensin | 2012 |
The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aze | 2012 |
Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Antioxidants; B | 2012 |
Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando
Topics: Aged; Albuminuria; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiot | 2012 |
L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.
Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2013 |
Titration of telmisartan, but not addition of amlodipine, reduces urine albumin in diabetic patients treated with telmisartan-diuretic.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzo | 2013 |
Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension.
Topics: Adult; Aged; Albuminuria; Amlodipine; Creatinine; Dihydropyridines; Double-Blind Method; Female; Hem | 2013 |
Amlodipine seems to be superior to valsartan in decreasing microalbuminuria in newly diagnosed hypertensive patients: a novel effect to be explained with hyperfiltration?
Topics: Adult; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; F | 2013 |
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blo | 2002 |
Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Ca | 2002 |
Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
Topics: Aged; Albuminuria; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channe | 2003 |
Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood.
Topics: Adolescent; Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Bl | 2003 |
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; A | 2005 |
Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphe | 2005 |
Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes.
Topics: Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazep | 2005 |
Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.
Topics: Adult; Aged; Albuminuria; Amlodipine; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Diabet | 2005 |
Clinical observation on Breviscapine in treating hypertension patients complicated with micro-albuminuria of renal impairment.
Topics: Adult; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; beta 2-Microglobulin; Blood Pressure; | 2005 |
Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy.
Topics: Adult; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, | 2005 |
Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphe | 2005 |
Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART).
Topics: Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabeti | 2007 |
Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzo | 2007 |
Add-on amlodipine improves arterial function and structure in hypertensive patients treated with an angiotensin receptor blocker.
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pre | 2007 |
Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
Topics: Albuminuria; Amlodipine; Antihypertensive Agents; Arteries; Calcium Channel Blockers; Dihydropyridin | 2007 |
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; A | 2008 |
Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; An | 2008 |
Effects of lisinopril and amlodipine on microalbuminuria and renal function in patients with hypertension.
Topics: Adult; Aged; Albuminuria; Amlodipine; Female; Hemodynamics; Humans; Hypertension; Kidney; Lisinopril | 1994 |
Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine.
Topics: Adult; Aged; Albuminuria; Amlodipine; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabe | 1994 |
Amlodipine in ambulatory hypertensive patients: humoral and haemodynamic effects.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Aldosterone; Amlodipine; Blood Pressure; Cholesterol; F | 1993 |
Albuminuria and transferrinuria in essential hypertension. Effects of antihypertensive therapy.
Topics: Adult; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; B | 1996 |
Comparison of losartan and amlodipine in renally impaired hypertensive patients.
Topics: Adult; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium; Creatine; Fe | 1998 |
Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Cross-Ove | 1998 |
Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.
Topics: Adult; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Ch | 2000 |
Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Cha | 2000 |
[Calcium channel blocking agents and albuminuria in diabetic and hypertensive patients. A pilot study].
Topics: Absorption; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Creati | 2000 |
Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Apolipoproteins; Apoprotein | 2002 |
12 other studies available for amlodipine and Albuminuria
| Article | Year |
|---|---|
Effects of benidipine, a long-acting T-type calcium channel blocker, on home blood pressure and renal function in patients with essential hypertension: a retrospective, 'real-world' comparison with amlodipine.
Topics: Adult; Aged; Albuminuria; Amlodipine; Blood Pressure; Calcium Channel Blockers; Calcium Channels, T- | 2009 |
Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats.
Topics: Albuminuria; Aldosterone; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; | 2011 |
The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; | 2010 |
Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats.
Topics: Albuminuria; Amides; Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus | 2012 |
Targeting albuminuria in arterial hypertension and diabetes: how is it best achieved and what is its clinical relevance?
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood P | 2013 |
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood P | 2003 |
Early blood pressure normalization independent of the class of antihypertensive agent prevents augmented renal fibronectin and albuminuria in experimental diabetic nephropathy.
Topics: Albuminuria; Amlodipine; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weigh | 2004 |
Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes.
Topics: Albuminuria; Amlodipine; Animals; Azo Compounds; Blood Pressure; Calcium Channel Blockers; Collagen | 2004 |
[Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diabetes | 2004 |
Albuminuria in diabetes mellitus: relation to ambulatory versus office blood pressure and effects of cilazapril.
Topics: Adolescent; Adult; Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pr | 1996 |
[Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].
Topics: Albuminuria; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
Effects of the calcium channel antagonist amlodipine in cats with surgically induced hypertensive renal insufficiency.
Topics: Albuminuria; Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Cat Diseases; Cats; Fema | 2002 |